Partnerships, Licensing, Investments and M&A Deals and Trends for May 2016 in Pharmaceuticals

Home/Partnerships, Licensing, Investments and M&A Deals and Trends for May 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2016 in Pharmaceuticals

Regulation & Policy (Pharma & Healthcare), Finance & Investment (Pharma & Healthcare), Deals & Alliances (Pharma & Healthcare), Pharma & Healthcare

Publication ID:

GDA0716050

Publication Date:

July 01, 2016

Pages:

Publisher:

GlobalData

Region:

Global

$1,000.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2016 in Pharmaceuticals

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for May 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in May 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 9
2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, May 2016 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, May 2016 14
2.2.1 AbbVie to Raise USD7.8 Billion in Public Offering of Notes 14
2.2.2 Mylan Prices Private Placement of Notes for USD6.5 Billion 14
2.2.3 Pfizer to Acquire Anacor Pharma for USD5.2 Billion 15
2.2.4 Pfizer Raises USD4.95 Billion in Public Offering of Notes 16
2.2.5 Biogen Enters into Co-Development Agreement with University of Pennsylvania 16
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, May 2016 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, May 2016 19
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, May 2016 20
3.1.1 Top M&A Deals in May 2016 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, December 2016 - May 2016 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, May 2016 23
3.2.1 Top Equity Offering Deals in May 2016 24
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, December 2016 - May 2016 25
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, May 2016 26
3.3.1 Top PE/VC Deals in May 2016 27
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, May 2016 28
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, May 2016 29
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, December 2016-May 2016 30
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2016-May 2016 31
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, May 2016 32
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, December 2016 - May 2016 34
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), May 2016 35
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, May 2016 36
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), December 2016 - May 2016 37
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, December 2016 - May 2016 39
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), December 2016 - May 2016 40
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2016 - May 2016 42
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2016 43
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2016 43
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2016 44
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), December 2016 - May 2016 45
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), December 2016 - May 2016 46
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), December 2016 - May 2016 47
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), December 2016 - May 2016 49
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, May 2016 50
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, May 2016 51
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, May 2016 52
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 53
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, May 2016 53
5.1.1 Oncology - Deals of the Month 54
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, May 2016 57
5.2.1 Central Nervous System - Deals of the Month 58
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, May 2016 61
5.3.1 Infectious Diseases - Deals of the Month 62
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, May 2016 64
5.4.1 Cardiovascular - Deals of the Month 65
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, May 2016 67
5.5.1 Immunology - Deals of the Month 68
5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, May 2016 71
5.6.1 Gastrointestinal - Deal of the Month 72
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, May 2016 73
5.7.1 Metabolic Disorders - Deal of the Month 74
6 Deal Summary by Geography 76
6.1 Pharmaceuticals & Healthcare, North America Deals, May 2016 76
6.1.1 North America - Deals of the Month 77
6.2 Pharmaceuticals & Healthcare, Europe, Deals, May 2016 80
6.2.1 Europe - Deals of the Month 81
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, May 2016 83
6.3.1 Asia-Pacific - Deals of the Month 84
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, May 2016 86
6.4.1 Rest of the World - Deals of the Month 87
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 88
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, December 2016 - May 2016 88
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, December 2016 - May 2016 89
8 Further Information 90
8.1 Methodology 90
8.2 About GlobalData 91
8.3 Disclosure information 91
8.4 Disclaimer 92

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, May 2016 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), May 2016 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, May 2016 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2016 - May 2016 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, May 2016 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 25
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 27
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, May 2016 27
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, December 2016 - May 2016 28
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), May 2016 30
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 31
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2016 - May 2016 31
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 33
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 34
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2016 - May 2016 35
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), May 2016 36
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2016 - May 2016 38
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2016 - May 2016 41
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), December 2016 - May 2016 42
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 43
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), December 2016 - May 2016 44
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 45
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), May 2016 46
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2016 - May 2016 48
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2016 50
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, May 2016 50
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, May 2016 51
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, May 2016 52
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 54
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 58
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 62
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 65
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 68
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 72
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 74
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 77
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 81
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 84
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 87
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 88
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 89

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), May 2016 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), May 2016 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 20
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2016 - May 2016 22
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 23
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 25
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 26
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2016 - May 2016 28
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), May 2016 29
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), May 2016 29
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 30
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 32
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 34
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2016 - May 2016 35
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2016 - May 2016 37
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2016 - May 2016 39
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2016 - May 2016 40
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2016 - May 2016 42
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 43
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2016 - May 2016 44
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 45
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2016 - May 2016 46
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, December 2016 - May 2016 47
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), December 2016 - May 2016 48
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), May 2016 49
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 53
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 57
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 61
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 64
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 67
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 71
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 73
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 76
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 80
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 83
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 86
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 88
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2016 - May 2016 89

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".